Search

Your search keyword '"O’Hehir, Robyn E."' showing total 666 results

Search Constraints

Start Over You searched for: Author "O’Hehir, Robyn E." Remove constraint Author: "O’Hehir, Robyn E."
666 results on '"O’Hehir, Robyn E."'

Search Results

2. Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants

9. Preface

10. Contributors

18. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study

19. Mind the gaps: Clinical trial concepts to address unanswered questions in aeroallergen immunotherapy—An NIAID/AHRQ Workshop

20. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

21. Third dose COVID-19 mRNA vaccine enhances IgG4 isotype switching and recognition of Omicron subvariants by memory B cells after with mRNA but not adenovirus priming

22. A recent patent in allergy & immunology: Biomarkers on allergen‐specific memory B cells to predict allergen immunotherapy outcome.

25. Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy.

26. Trait profiles in difficult‐to‐treat asthma: Clinical impact and response to systematic assessment

28. COVID-19 adenoviral vector vaccination elicits a robust memory B cell response with the capacity to recognize Omicron BA.2 and BA.5 variants

33. RNA sequencing of single allergen‐specific memory B cells after grass pollen immunotherapy: Two unique cell fates and CD29 as a biomarker for treatment effect

37. Dedication

38. Preface

40. Phenotypic Distinctions Between Omega-5-Gliadin Allergy and Peanut Allergy: Clinical Profile, Reaction Rates and Triggers, and Quality of Life

41. The second COVID‐19 mRNA vaccine dose enhances the capacity of Spike‐specific memory B cells to bind Omicron BA.2.

42. RNA sequencing of single allergen‐specific memory B cells after grass pollen immunotherapy: Two unique cell fates and CD29 as a biomarker for treatment effect.

50. Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK-air (R)

Catalog

Books, media, physical & digital resources